Novavax, Inc. NVAX shares are trading higher in sympathy with Moderna Inc MRNA, which reported better-than-expected second-quarter results.
Quarterly revenue for Moderna was $4.75 billion compared to $4.34 million a year ago, beating the consensus of $4.07 billion.
Moderna has authorized an additional share repurchase program for $3 billion. The $3 billion repurchase program announced in February is continuing and currently has approximately $1 billion outstanding... Read More
See Also: Why Kintara Therapeutics Stock Is Skyrocketing Today
According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $34.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.